A Review of PI3K Inhibitors in B-Cell Malignancies

Area of Science:

• Oncology
• Pharmacology

Background:

• The phosphoinositide 3-kinase (PI3K) pathway is vital for cell growth and metabolism.
• Targeting the PI3K pathway is a key strategy in cancer drug development.

Purpose of the Study:

• To review current data on U.S. Food & Drug Administration-approved PI3K inhibitors for B-cell malignancies.
• To discuss adverse event management and clinical implications for healthcare providers.

Main Methods:

• Review of current clinical data and FDA-approved PI3K inhibitors.
• Analysis of drug selectivity, indications, dosing, and toxicities.
• Discussion of ongoing research for expanded use and combination therapies.

Main Results:

• Idelalisib, copanlisib, and duvelisib are approved for hematologic malignancies.
• These inhibitors vary in isoform selectivity, indications, and toxicity profiles.
• Ongoing studies explore new applications and combination regimens.

Conclusions:

• Approved PI3K inhibitors offer therapeutic options for B-cell malignancies.
• Understanding individual drug profiles and managing toxicities is essential.
• Further research will likely expand the role of PI3K inhibitors in oncology.